Mr. Marc Edwards reports

KANE BIOTECH ANNOUNCES EXTENSION OF TERM OF CREDIT FACILITY

Kane Biotech Inc. has entered into an amending agreement with Pivot Financial I LP to the amended and restated credit agreement between the company and Pivot dated Aug. 31, 2021, extending the maturity date of its credit facility from Jan. 31, 2023, to Feb. 28, 2023. Kane and Pivot are working toward finalizing a longer term extension to the credit facility and this extension provides time for that to be completed.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech.

We seek Safe Harbor.